Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia due to impaired insulin secretion, reduced insulin action (insulin resistance), or both. Clinically, diabetes is diagnosed using criteria such as hemoglobin A1c, fasting plasma glucose, or elevated glucose on an oral glucose tolerance test. The central pathological theme is that when glucose remains elevated over time, it participates in multiple biochemical pathways that injure vascular endothelium, accelerate atherosclerosis, impair microcirculation, and disrupt cellular metabolism.
In type 1 diabetes, autoimmune destruction of pancreatic beta cells leads to absolute insulin deficiency. Without insulin, glucose cannot enter insulin-sensitive tissues effectively, producing rapid hyperglycemia and a tendency toward ketosis if untreated. Type 2 diabetes, which accounts for the majority of cases, develops gradually in the setting of insulin resistance, progressive beta-cell dysfunction, and altered hepatic glucose output. Environmental factors—including excess caloric intake, sedentary behavior, and weight gain—interact with genetic susceptibility and adipose-driven inflammatory signaling.
A key mechanism linking elevated blood glucose to disease is non-enzymatic glycation of proteins and lipids, forming advanced glycation end products (AGEs). AGEs stiffen and thicken vascular structures, promote oxidative stress, and engage receptor-mediated inflammatory pathways. Hyperglycemia also increases mitochondrial reactive oxygen species, activates protein kinase C isoforms, and enhances polyol and hexosamine pathways. Together, these changes compromise endothelial function, disturb nitric oxide signaling, and raise the risk of both microvascular and macrovascular complications.
Microvascular damage classically manifests as diabetic retinopathy, nephropathy, and neuropathy. In the retina, capillary leakage and ischemia lead to vision-threatening changes; in the kidney, glomerular hyperfiltration and basement membrane thickening progress to albuminuria and chronic kidney disease; in peripheral nerves, demyelination and axonal injury cause pain, numbness, and autonomic dysfunction. Macrovascular complications include coronary artery disease, stroke, and peripheral arterial disease, driven by accelerated atherosclerosis, dyslipidemia, and chronic inflammatory activation.
Symptoms of hyperglycemia can include polyuria, polydipsia, weight loss, blurred vision, and fatigue; however, type 2 diabetes may be asymptomatic for years due to gradual progression. Acute complications include diabetic ketoacidosis (more common in type 1) and hyperosmolar hyperglycemic state (more common in type 2), both reflecting profound insulin deficiency or resistance with dehydration and electrolyte derangements.
Management aims to normalize glycemia and reduce complications while addressing cardiovascular risk. Lifestyle intervention is foundational: weight reduction for overweight patients, dietary patterns emphasizing minimally processed foods, and regular physical activity improve insulin sensitivity through skeletal muscle glucose uptake and improved lipid metabolism. Pharmacologic therapy is individualized based on type of diabetes, glycemic targets, comorbidities, and contraindications. Metformin is commonly used for type 2 diabetes due to its hepatic glucose-lowering effects and favorable safety profile. Additional agents may include GLP-1 receptor agonists and SGLT2 inhibitors, which can provide both glycemic benefits and organ-protective effects, particularly in patients with established cardiovascular disease or chronic kidney disease. Insulin is essential for type 1 diabetes and may be required for type 2 when beta-cell function declines or when control is inadequate.
Monitoring includes regular A1c testing, home glucose monitoring when appropriate, screening for complications (eye exams, urine albumin testing, and foot evaluations), and assessment of cardiovascular risk factors such as blood pressure and lipid levels. Comprehensive care often involves risk reduction strategies: smoking cessation, blood pressure control, statin therapy when indicated, and vaccination updates.
Preventive strategies focus on delaying or preventing type 2 diabetes in at-risk individuals. Evidence supports that modest weight loss, increased physical activity, and dietary changes can significantly reduce progression from prediabetes to diabetes. Prediabetes reflects insulin resistance and early dysglycemia; prompt intervention can improve insulin sensitivity and reduce long-term microvascular injury.
Finally, patient education is crucial because diabetes is both biochemical and behavioral. Sustained outcomes depend on adherence to treatment, recognition of hypo- and hyperglycemia symptoms, and shared decision-making regarding diet, medications, and targets. When glucose control is optimized, the trajectory of vascular and organ injury can be slowed, improving quality of life and reducing morbidity and mortality.
Source: [@Fathers_Diary]
Fathers Diary: Sugar in the wrong places steals your health. Choose nature’s sweets instead. Sugar in your blood? That’s diabetes. Sugar in your brain? Dementia. Sugar in your teeth? Cavities. Sugar in your liver? Fatty liver disease. Sugar deep in your cells? Oxidative stress and. #breaking
— @Fathers_Diary May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
